[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.226.208.185. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
April 3, 2018

Lipid Lowering in Acute Coronary Syndrome: Is Treatment Early Enough?

Author Affiliations
  • 1South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, South Australia, Australia
JAMA. 2018;319(13):1325-1326. doi:10.1001/jama.2018.2426

The beneficial effect of lipid lowering with statins in randomized clinical trials has had a profound effect on patient outcomes and informing treatment algorithms for cardiovascular prevention. These studies have increasingly emphasized the importance of the direct relationship between the degree of lipid lowering and clinical benefit, with the greatest effect observed among patients at the highest risk of having a subsequent cardiovascular event.1 Such observations have informed treatment guidelines, which strongly advocate for use of intensive statin therapy for patients with the highest cardiovascular risk.2

×